The Australian Autoimmune Haemolytic Anaemia (AIHA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Autoimmune Haemolytic Anaemia (AIHA) is an autoimmune disorder characterised by the premature destruction of healthy red blood cells (RBCs) by auto-antibodies. It is a common disorder directed against self RBCs which can be idiopathic (primary) or secondary. In w-AIHA, the autoantibodies react optimally with the RBCs at 37C. Normally, red blood cells live in the body for 100 to 120 days. However, in severe cases of AIHA, the cells may remain only for a few days. In children, it is a rare condition that is usually temporary. In some adults, however, AIHA can be a long-term condition that returns frequently. AIHA can develop rapidly or over time. A decreased number of red blood cells (anemia) may cause fatigue, weakness, a pale skin color (pallor), dizziness, palpitations, and shortness of breath (dyspnea).
Recently in June, 2020, 5 cases of AIHA were reported in Australia. Serologically, cases are divided into warm, cold (cold haemagglutinin disease and paroxysmal cold haemoglobinuria) or mixed AIHA.
The market for Autoimmune Haemolytic Anaemia (AIHA) is primarily driven by a rise in the usage of medications for patients with Autoimmune Haemolytic Anaemia, such as corticosteroids. Because of the fast growing geriatric population, the prevalence of AIHA is increasing. Because the older population has a lower immune system, they are more susceptible to diseases, which fuels market growth. The steady increase in the use of immunoglobulin for treatment of off-label indications is expected to drive the market during the forecast period. Technological improvements in the production and purification methods of intravenous immunoglobulins (IVIG) have made these safer and free from protein, viral, or any other contaminants. This has increased clinician preference for usage of IVIG. This in turn, boosts the market growth during the forecast period.
When compared to materials and methods utilised in the production of traditional pharmaceutical goods, plasma collection and manufacturing methods are expensive. Furthermore, because Intravenous Immunoglobulin (IVIG) products are obtained from blood, more sophisticated collection, purification, and storage processes are necessary.